Regenerative Medicine Market in the US 2017-2021

Regenerative Medicine Market in the US 2017-2021

About Regenerative Medicine Market in the US

Regenerative medicine is a bioproduct, which is developed by using translational research techniques such as molecular biology, tissue engineering, and gene engineering. Stem cells and tissue scaffolds have the effective therapeutic potential, which has increased the adoption of regenerative medicine in the US market. Stem cell therapy responds well to various treatments such as dermatological, macular, musculoskeletal, and cardiovascular applications. The regenerative medicine industry includes four key sectors, which help the vendors to develop regenerative medicine.Technavio’s analysts forecast the Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the Regenerative Medicine Market in the US for 2017-2021. To calculate the market size, the report considers the sales, volume, and value of regenerative medicine market in the US.Technavio's report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Acelity
• Medtronic
• MiMedx
• Organogenesis
• Zimmer Biomet

Other prominent vendors

• ACE Surgical Supply
• Acera Surgical
• Acologix
• Advanced Biologics
• AlloCure
• AlloSource
• Alphatec Spine
• ANTEROGEN
• Antibe Therapeutics
• Astellas Pharma
• Athersys
• Avita Medical
• AxoGen
• Bacterin International
• Baxter
• Bellicum Pharmaceuticals
• BioCardia
• Biogen
• BioRestorative Therapies
• Biostage
• Bio-Tissue
• BioTissue
• bluebird bio
• BONESUPPORT
• BrainStorm Cell Therapeutics
• Caladrius
• Calimmune
• Capricor Therapeutics
• CELGENE
• Cell Medica
• Cell Therapy
• CellBioMed
• CellSeed
• Celyad
• CESCA THERAPEUTICS
• CTM CRC
• CryoLife
• Cynata
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• DiscGenics
• Fate Therapeutics
• Fibrocell Science
• Forticell Bioscience
• Fortress Biotech
• FUJIFILM Holdings
• Gamida Cell
• Geron
• GlaxoSmithKline
• Healthpoint (acquired by Smith & Nephew)
• Histogen
• Histogenics
• Holostem Terapie Avanzate
• Humacyte
• Immunocellular Therapeutics
• Integra LifeSciences
• Intercytex
• InVivo Therapeutics
• iSTO Biologics
• Janssen Pharmaceuticals
• Juno Therapeutics
• Juventas Therapeutics
• Kiadis Pharma
• LifeCell
• LifeNet Health
• Living Cell Technologies
• Lonza
• MaxCyte
• MEDIPOST
• Mesoblast
• Nanofiber Solutions
• Nanotope
• Neuralstem
• NewLink Genetics
• Northwest Biotherapeutics
• NovaRx
• Opexa Therapeutics
• ORGANOVO HOLDINGS
• Orteq
• Orthofix Holdings
• Osiris Therapeutics
• Pfizer
• PHARMICELL
• Pluristem
• Prima BioMed
• Q Therapeutics
• Regenerex
• Regenerys
• Regience
• Regrow
• RENOVA THERAPEUTICS
• RepliCel
• ReproCELL
• RhinoCyte
• Rohto Pharma
• RTI Surgical
• SanBio
• Sangamo Therapeutics
• Shanghai Sunway Biotech
• Shire
• Stratatech
• SURGILOGIX
• Synergistic Technologies
• TAKARA BIO
• tella
• Tissue Genesis
• TissueGene
• Txcell
• VentriNova
• Vericel
• ViaCyte
• VistaGen Therapeutics

Market driver

• CVD and diabetes in young adult and aging population
• For a full, detailed list, view our report

Market challenge

• High cost of clinical trial
• For a full, detailed list, view our report

Market trend

• Increasing strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Releases

Technavio Announces the Publication of its Research Report – Regenerative Medicine Market in the US 2017-2021

Technavio recognizes the following companies as the key players in the regenerative medicine market in the US: Acelity, Medtronic, MiMedx, Organogenesis, and Zimmer Biomet

Other Prominent Vendors in the market are: ACE Surgical Supply, Acera Surgical, Acologix, Advanced Biologics, AlloCure, AlloSource, Alphatec Spine, ANTEROGEN, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen, BioRestorative Therapies, Biostage, Bio-Tissue, BioTissue, bluebird bio, BONESUPPORT, BrainStorm Cell Therapeutics, Caladrius, Calimmune, Capricor Therapeutics, CELGENE, Cell Medica, Cell Therapy, CellBioMed, CellSeed, Celyad, CESCA THERAPEUTICS, CTM CRC, CryoLife, Cynata, Cytori Therapeutics, Dendreon Pharmaceuticals, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM Holdings, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Biologics, Janssen Pharmaceuticals, Juno Therapeutics, Juventas Therapeutics, Kiadis Pharma, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, Northwest Biotherapeutics, NovaRx, Opexa Therapeutics, ORGANOVO HOLDINGS, Orteq, Orthofix Holdings, Osiris Therapeutics, Pfizer, PHARMICELL, Pluristem, Prima BioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RENOVA THERAPEUTICS, RepliCel, ReproCELL, RhinoCyte, Rohto Pharma, RTI Surgical, SanBio, Sangamo Therapeutics, Shanghai Sunway Biotech, Shire, Stratatech, SURGILOGIX, Synergistic Technologies, TAKARA BIO, tella, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, and VistaGen Therapeutics.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increasing strategic alliances. Major vendors are entering into strategic alliances with other vendors for drug development and manufacturing. The trend is anticipated during the forecast period. Leading vendors in the market are undertaking M&A to strengthen their global position and to improve their commercial capabilities. Through increasing strategic alliances, many companies are receiving upfront and royalty payment, which encourages many small companies to involve into R&D and develop novel regenerative medicine products.”

According to the report, one of the major drivers for this market is CVD and diabetes in young adult and aging population. CVD is a common disease in the older population; however, it is growing high among young adults owing to lifestyle and over-indulgement in junk foods. A combined study conducted by the Department of Clinical and Experimental Medicine, University of Florence; Department of Health Sciences, University of Milano-Bicocca; and Department of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, Italy in 2015, found that uncontrolled blood pressure increases the risk of CVDs such as stroke and heart attack.

Further, the report states that one of the major factors hindering the growth of this market is High cost of clinical trial. In high-income countries such as the US, the cost of clinical trials and product launch leads the vendors to spend in millions. Most of the small vendors or start-up biotech companies seek government or private funding, but most of the organizations provide the limited amount or grant funding to vendors if the targeted goal is completed. A combined study conducted by John A. Paulson School of Engineering and Applied Sciences, Harvard University and Wyss Institute for Biologically Inspired Engineering at Harvard University, US, in 2015, found that, to receive the FDA approval, pharma and biologics companies, which are into development of regenerative medicine, spend around $802-$2.6 billion for each product approval.

Companies Mentioned

Acelity, Medtronic, MiMedx, Organogenesis, Zimmer Biomet, ACE Surgical Supply, Acera Surgical, Acologix, Advanced Biologics, AlloCure, AlloSource, Alphatec Spine, ANTEROGEN, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen, BioRestorative Therapies, Biostage, Bio-Tissue, BioTissue, bluebird bio, BONESUPPORT, BrainStorm Cell Therapeutics, Caladrius, Calimmune, Capricor Therapeutics, CELGENE, Cell Medica, Cell Therapy, CellBioMed, CellSeed, Celyad, CESCA THERAPEUTICS, CTM CRC, CryoLife, Cynata, Cytori Therapeutics, Dendreon Pharmaceuticals, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM Holdings, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Biologics, Janssen Pharmaceuticals, Juno Therapeutics, Juventas Therapeutics, Kiadis Pharma, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, Northwest Biotherapeutics, NovaRx, Opexa Therapeutics, ORGANOVO HOLDINGS, Orteq, Orthofix Holdings, Osiris Therapeutics, Pfizer, PHARMICELL, Pluristem, Prima BioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RENOVA THERAPEUTICS, RepliCel, ReproCELL, RhinoCyte, Rohto Pharma, RTI Surgical, SanBio, Sangamo Therapeutics, Shanghai Sunway Biotech, Shire, Stratatech, SURGILOGIX, Synergistic Technologies, TAKARA BIO, tella, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, and VistaGen Therapeutics.